Cuilin Zhang1, Rajeshwari Sundaram2, José Maisog2, Antonia M Calafat3, Dana Boyd Barr4, Germaine M Buck Louis2. 1. Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Rockville, Maryland. Electronic address: zhangcu@mail.nih.gov. 2. Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Rockville, Maryland. 3. Division of Laboratory Sciences, Centers for Disease Control and Prevention, Atlanta, Georgia. 4. Department of Occupational and Environmental Health and Rollins School of Public Health, Emory University, Atlanta, Georgia.
Abstract
OBJECTIVE: To examine preconception serum concentrations of perfluorooctanoic acid (PFOA) and six other PFCs in relation to gestational diabetes (GDM) risk. DESIGN: Prospective cohort with longitudinal follow-up. SETTING: Not applicable. PATIENT(S): Among 501 women recruited upon discontinuing contraception for the purpose of becoming pregnant, 258 (51%) became pregnant and were eligible for the study, of which 28 (11%) reported having physician-diagnosed GDM during follow-up. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): The odds ratios (ORs) and 95% confidence intervals (CIs) of GDM associated with each standard deviation (SD) increment of preconception serum PFOA concentration (ng/mL, log-transformed) and six other PFCs were estimated with the use of logistic regression after adjusting for age, prepregnancy body mass index, smoking, and parity conditional on gravidity. RESULT(S): Preconception geometric mean (95% CI) PFOA concentrations (in ng/mL) were higher for women with than without GDM (3.94 [3.15-4.93] vs. 3.07 [2.83-3.12], respectively). Each SD increment in PFOA was associated with a 1.87-fold increased GDM risk (adjusted OR 1.86 [95% CI 1.14-3.02]). A slightly increased risk associated with each SD increment for the six other PFCs was observed as well (all ORs >1.0, range 1.06-1.27), although the associations were not statistically significant. CONCLUSION(S): Our findings suggested that higher environmentally relevant concentrations of PFOA were significantly associated with an increased risk of GDM. If corroborated, these findings may be suggestive of a possible environmental etiology for GDM. Published by Elsevier Inc.
OBJECTIVE: To examine preconception serum concentrations of perfluorooctanoic acid (PFOA) and six other PFCs in relation to gestational diabetes (GDM) risk. DESIGN: Prospective cohort with longitudinal follow-up. SETTING: Not applicable. PATIENT(S): Among 501 women recruited upon discontinuing contraception for the purpose of becoming pregnant, 258 (51%) became pregnant and were eligible for the study, of which 28 (11%) reported having physician-diagnosed GDM during follow-up. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): The odds ratios (ORs) and 95% confidence intervals (CIs) of GDM associated with each standard deviation (SD) increment of preconception serum PFOA concentration (ng/mL, log-transformed) and six other PFCs were estimated with the use of logistic regression after adjusting for age, prepregnancy body mass index, smoking, and parity conditional on gravidity. RESULT(S): Preconception geometric mean (95% CI) PFOA concentrations (in ng/mL) were higher for women with than without GDM (3.94 [3.15-4.93] vs. 3.07 [2.83-3.12], respectively). Each SD increment in PFOA was associated with a 1.87-fold increased GDM risk (adjusted OR 1.86 [95% CI 1.14-3.02]). A slightly increased risk associated with each SD increment for the six other PFCs was observed as well (all ORs >1.0, range 1.06-1.27), although the associations were not statistically significant. CONCLUSION(S): Our findings suggested that higher environmentally relevant concentrations of PFOA were significantly associated with an increased risk of GDM. If corroborated, these findings may be suggestive of a possible environmental etiology for GDM. Published by Elsevier Inc.
Authors: Christopher Lau; Julie R Thibodeaux; Roger G Hanson; Michael G Narotsky; John M Rogers; Andrew B Lindstrom; Mark J Strynar Journal: Toxicol Sci Date: 2006-01-16 Impact factor: 4.849
Authors: Dana Dabelea; Janet K Snell-Bergeon; Cynthia L Hartsfield; Kimberly J Bischoff; Richard F Hamman; Robert S McDuffie Journal: Diabetes Care Date: 2005-03 Impact factor: 19.112
Authors: Gerald L Kennedy; John L Butenhoff; Geary W Olsen; John C O'Connor; Andrew M Seacat; Roger G Perkins; Lisa B Biegel; Sandra R Murphy; David G Farrar Journal: Crit Rev Toxicol Date: 2004 Jul-Aug Impact factor: 5.635
Authors: Assiamira Ferrara; Henry S Kahn; Charles P Quesenberry; Candice Riley; Monique M Hedderson Journal: Obstet Gynecol Date: 2004-03 Impact factor: 7.661
Authors: Geary W Olsen; Jean M Burris; David J Ehresman; John W Froehlich; Andrew M Seacat; John L Butenhoff; Larry R Zobel Journal: Environ Health Perspect Date: 2007-09 Impact factor: 9.031
Authors: Melissa M Smarr; Katherine L Grantz; Cuilin Zhang; Rajeshwari Sundaram; José M Maisog; Dana Boyd Barr; Germaine M Buck Louis Journal: Sci Total Environ Date: 2016-02-12 Impact factor: 7.963
Authors: Damaskini Valvi; Youssef Oulhote; Pal Weihe; Christine Dalgård; Kristian S Bjerve; Ulrike Steuerwald; Philippe Grandjean Journal: Environ Int Date: 2017-07-25 Impact factor: 9.621
Authors: Andres Cardenas; Marie-France Hivert; Diane R Gold; Russ Hauser; Ken P Kleinman; Pi-I D Lin; Abby F Fleisch; Antonia M Calafat; Xiaoyun Ye; Thomas F Webster; Edward S Horton; Emily Oken Journal: Diabetes Care Date: 2019-07-11 Impact factor: 19.112
Authors: Emma V Preston; Sheryl L Rifas-Shiman; Marie-France Hivert; Ami R Zota; Sharon K Sagiv; Antonia M Calafat; Emily Oken; Tamarra James-Todd Journal: J Clin Endocrinol Metab Date: 2020-08-01 Impact factor: 5.958